2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.124 Danielle Dressler NACLC23 Abstract

PP01.124 Danielle Dressler NACLC23 Abstract

Pdf Summary

This study aimed to evaluate the impact of comprehensive versus limited next-generation sequencing (NGS) testing on the time to an actionable result and time to treatment in patients with advanced non-small cell lung cancer (NSCLC). The researchers analyzed data from patients diagnosed with lung cancer at Northwestern Memorial Hospital (NMH), Central DuPage Hospital (CDH), and Delnor Hospital (D) between January 2019 and December 2020.<br /><br />Out of 106 stage IV NSCLC patients diagnosed at CDH or D, 85% underwent NGS testing. Among them, 32% had comprehensive testing, while 68% had limited testing. The median time to actionable results was 26 days for comprehensive testing and 22 days for limited testing, with the former showing a significant delay. However, there was no significant difference in the time from the first biopsy to the initiation of treatment between the two groups.<br /><br />The study findings suggest that comprehensive NGS testing, although associated with longer times to actionable results, does not significantly affect the time to treatment initiation in advanced NSCLC. These results support the use of comprehensive molecular profiling in settings where reflexive, internal molecular testing is not available.<br /><br />The use of NGS testing has been shown to detect actionable mutations and improve overall survival in NSCLC patients. This study provides insights into the practical implications of NGS testing in a clinical setting and highlights the importance of timely results for effective treatment decision-making.<br /><br />It is worth noting that this study was limited to a specific hospital system and a relatively small sample size. Further research is needed to validate these findings and explore the impact of different testing approaches in larger and more diverse patient populations. Nonetheless, the results contribute to our understanding of the role of comprehensive NGS testing in the management of advanced NSCLC.

Keywords

next-generation sequencing

comprehensive testing

limited testing

time to actionable result

time to treatment

non-small cell lung cancer

NSCLC

Northwestern Memorial Hospital

Central DuPage Hospital

Delnor Hospital